Keyphrases
Acute COVID-19
8%
Adaptive Immune Response
6%
Advanced Hepatocellular Carcinoma
8%
Adverse Events
6%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
6%
Antibody Response
10%
Anticancer Immune Response
10%
Atezolizumab Plus Bevacizumab
6%
B Cells
12%
Bone Marrow
10%
Breast Cancer
6%
Cancer Cells
9%
Cancer Immunotherapy
18%
Cancer Vaccine
8%
Cancer-testis Antigen
9%
CD8+
7%
CD8+ T Cells
17%
Cell Population
8%
Checkpoint Blockade
7%
Clinical Outcomes
13%
Clinical Response
6%
Clinical Trials
10%
Confidence Interval
6%
COVID-19
42%
Crohn's Disease
8%
CyTOF
23%
Dendritic Cells
23%
Dengue Virus
7%
Epitope
6%
Glioblastoma
9%
Granulocyte Colony-stimulating Factor (G-CSF)
7%
Hepatocellular Cancer
6%
Hepatocellular Carcinoma
39%
High-risk Human Papillomavirus (HR-HPV)
6%
Host Response
6%
Immune Cells
15%
Immune Checkpoint Blockade
6%
Immune Checkpoint Inhibitor Therapy
6%
Immune Checkpoint Inhibitors
30%
Immune Landscape
6%
Immune Markers
6%
Immune Microenvironment
9%
Immune Monitoring
9%
Immune Parameters
12%
Immune Profiling
9%
Immune Response
21%
Immune System
7%
Immuno-oncology
13%
Immunogenicity
7%
Immunophenotyping
13%
In Cancer
15%
Inflammation
14%
Inflammatory Response
6%
Innate Immune Response
14%
Interferon-α (IFN-α)
8%
Ipilimumab
9%
Lipopolysaccharide
8%
Liver
7%
Lung
7%
Lung Cancer
6%
Macrophages
17%
Mass Cytometry
23%
Melanoma
12%
Monocytes
13%
Monotherapy
8%
Mount Sinai
8%
Multiple Myeloma
16%
Myeloid Cells
9%
Natural Killer Cells
9%
Neoantigen
8%
Nivolumab
12%
Non-small Cell Lung Cancer (NSCLC)
8%
NY-ESO-1
19%
Oncology Biomarkers
9%
Ovarian Cancer
6%
Overall Survival
16%
PD-1 Blockade
8%
Peripheral Blood
6%
Peripheral Blood Mononuclear Cells
10%
Peripheral Immune Cells
11%
Phase II Trial
10%
Programmed Death-ligand 1 (PD-L1)
25%
Progression-free Survival
11%
Randomized Trial
8%
Regulatory T Cells
6%
SARS-CoV-2 Infection
6%
Single-cell Analysis
9%
Single-cell RNA Sequencing (scRNA-seq)
9%
Solid Tumors
6%
T Cells
31%
Toll-like
6%
Treatment-related Adverse Events
7%
Tumor
29%
Tumor Antigen
7%
Tumor Cells
8%
Tumor Immunity
12%
Tumor Microenvironment
12%
Ulcerative Colitis
6%
Vaccination
8%
Whole Blood
10%
Immunology and Microbiology
Adoptive Immunity
7%
Antibody Response
7%
Atezolizumab
5%
B Cell
14%
Bevacizumab
6%
Blood Plasma
7%
Cancer Cell
7%
Cancer Testis Antigen
6%
CD4
5%
CD8
9%
Cell Population
8%
Chemokine
5%
COVID-19
28%
Crohn's Disease
8%
CTLA-4
5%
Cytokine
18%
Cytotoxic T-Cell
20%
Dendritic Cell
19%
Dengue Virus
6%
Epitope
10%
Gene Expression
8%
Granulocyte Macrophage Colony-Stimulating Factor
6%
Hepatitis C
6%
Human Immunodeficiency Virus
14%
Human Leukocyte Antigen
5%
Humoral Immunity
7%
Immune Checkpoint Blockade
5%
Immune Landscape
7%
Immune Response
28%
Immune System
7%
Immunity
100%
Immunocompetent Cell
24%
Immunofluorescence
7%
Immunogenicity
5%
Immunology
17%
Immunotherapy
38%
Inflammation Response
7%
Innate Immune System
5%
interferon
11%
Interleukin 6
8%
Intravenous Immunoglobulin
11%
Ipilimumab
7%
Lymphocyte
6%
Macrophage
21%
Mass Cytometry
18%
Memory T Cell
5%
Mouse Model
6%
Multiple Myeloma
19%
Myeloid
21%
Natural Killer Cell
8%
Neck
7%
Neoantigen
11%
Neutrophil
6%
Overall Survival
10%
Peripheral Blood Mononuclear Cell
9%
Plasmablast
5%
Programmed Death-Ligand 1
10%
Progression Free Survival
9%
Regulatory T Cell
9%
RNA Sequence
11%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Single Cell Analysis
8%
Squamous Cell
7%
T Cell
51%
T Cell Receptor
5%
T Cell Subset
5%
T-Helper Cell
14%
Toll-Like Receptor
5%
Tumor Antigen
6%
Tumor Cell
5%
Tumor Necrosis Factor
10%
Tumor Vaccine
6%
Ulcerative Colitis
5%
Upregulation
7%
Viral Disease
5%
Wart Virus
5%
Medicine and Dentistry
Adverse Event
11%
Biological Marker
31%
Breast Cancer
6%
Cancer Cell
5%
Cancer Immunotherapy
6%
Cell Population
5%
Cisplatin
5%
Clinical Trial
15%
COVID-19
33%
CTLA-4
7%
Cytokine
9%
Cytometry
6%
Cytotoxic T-Cell
11%
Dendritic Cell
12%
Disease
21%
Durvalumab
5%
Epitope
5%
Gemcitabine
5%
Gene Expression
7%
Hepatocellular Carcinoma
33%
Human Immunodeficiency Virus
10%
Immune Checkpoint Inhibitor
26%
Immune Response
22%
Immunity
52%
Immunocompetent Cell
12%
Immunofluorescence
5%
Immunoglobulin
12%
Immunohistochemistry
8%
Immunophenotyping
5%
Immunotherapy
44%
Infection
12%
Interferon
8%
Ipilimumab
8%
Lung
6%
Lung Cancer
7%
Lymphocyte
5%
Macrophage
16%
Malignant Neoplasm
44%
Mass Cytometry
8%
Medicine
6%
Melanoma
12%
Multiple Myeloma
9%
Myeloid Cell
5%
Neoplasm
44%
Nivolumab
11%
Non Small Cell Lung Cancer
7%
Oncology
11%
Overall Survival
16%
Programmed Death-Ligand 1
10%
Progression Free Survival
14%
Proteomics
5%
RNA Sequence
7%
Serositis
7%
Severe Acute Respiratory Syndrome Coronavirus 2
13%
Solid Malignant Neoplasm
5%
T Cell
24%
T-Cell Response
5%
Tumor Antigen
5%
Tumor Microenvironment
8%